Insomnia and daytime sleepiness are common complaints among night shift workers, but
effective sleep treatments in shift workers are lacking. The aim of this Phase IV
double-blind, placebo-controlled, randomized study is to test whether a dual orexin
antagonist, Lemborexant (5mg or 10mg), which would be expected to block the clock-driven
orexin-mediated wakefulness during the day, will increase daytime sleep time in shift workers
who complain of difficulty sleeping during the daytime compared to placebo.